Invesco
KNTE

Invesco’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Invesco’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-8,906
Closed -$205K – 4120
2021
Q3 		$205K Buy
+8,906
New +$194K ﹤0.01% 3796
2021
Q1 		– Sell
-167,383
Closed -$6.66M – 3964
2020
Q4 		$6.66M Buy
+167,383
New +$6.72M ﹤0.01% 2036

Other funds holding KNTE

FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Invesco's KNTE Position: Q4 2021 in Review

Invesco sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q4 2021, closing a stake of 8,906 shares — an estimated $205K sold.

Invesco first reported a position in KNTE in Q4 2020 and held it in 2 quarters. The position peaked at $6.66M in Q4 2020. 71 funds tracked by Wall St. Rank hold KNTE as of Q4 2021.

  • Invesco reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Invesco sold 8,906 Kinnate Biopharma Inc. Common Stock shares in Q4 2021, an estimated $205K.
  • Invesco first reported a position in Kinnate Biopharma Inc. Common Stock in Q4 2020 and held it in 2 quarters.
  • Invesco's Kinnate Biopharma Inc. Common Stock position peaked at $6.66M in Q4 2020.
  • 71 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q4 2021.

Based on Invesco's 13F filing for Q4 2021, filed 14 Feb 2022.